Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meth bill

This article was originally published in The Tan Sheet

Executive Summary

"Methamphetamine Blister Pack Loophole Elimination Act of 2004" (HR 3789), introduced in House Feb. 10 by Collin Peterson (D-Minn.), mirrors bill introduced by Sen. Dianne Feinstein (D- Calif.). Bill would eliminate exemption for blister-pack pseudoephedrine products from 9 g sales limit on bottled products (1"The Tan Sheet" Oct. 27, 2003, In Brief)...

You may also be interested in...



Meth blister pack bill

Blister-packed pseudoephedrine products would be subject to 9 gram retail sales limit applied to bottled products under "Methamphetamine Blister Pack Loophole Elimination Act of 2003" (S 1784) introduced Oct. 22 by Sen. Dianne Feinstein. Bill cites 2002 DEA study recommending limit, noting presence of blister packs at meth labs. Feinstein and others have introduced similar measures in the past. CHPA continues to object to uniform 9 g threshold, saying limit will not prevent diversion of products to labs. Bill was referred to Senate Judiciary Committee...

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS096482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel